| 摘要: |
| 监管科学研究通过监管工具、标准、方法等系列创新,持续提升我国药品科学监管水平,促进科技创新和临床转化应用。药品监管机构在推进这一进程中具有重要的地位和作用。本文选取细胞基因治疗这一前沿技术领域,通过回顾分析2019年以来我国药品监督管理相关机构发表的论文,研究我国监管科学研究生态和药品监管机构在研究中的角色,通过与美国食品药品监督管理局(FDA)该领域监管科学研究成果的对比分析,提出优化监管科学成果转化体系的建议。 |
| 关键词: 监管科学 药品监管 细胞基因 |
| DOI:10.13506/j.cnki.jpr.2026.01.007 |
| 基金项目:国家药品监督管理局高级研修学院支持项目(No.NMPAIED 102024003) |
|
Publication Date:January 26, 2026
|
|
| Analysis of the characteristics and optimization path of regulatory scientific research in the field of cell gene therapy in China |
| SUN Tanlin |
| (National Medical Products Administration Institute of Executive Development , Beijing 100073, China) |
| Abstract: |
| Regulatory science research drives high-level studies and efficient translation in China's pharmaceutical regulatory science through innovations in regulatory tools, standards, and methodologies. Regulatory agencies play a crucial role in this process. This paper focused on the field of cell and gene therapy,analyzing articles published by relevant national pharmaceutical regulatory institutions to explore the curent regulatory science research ecosystem in China and the role of regulatary agencies within this domain. Based on these findings, we propose optimization suggestions to promote the development of regulatory science research,enhance pharmaceutical regulatory capabilities and accelerate the market entry of innovative products. |
| Key words: Drug regulation Regulatory science Cell and gene therapy |